Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at- http://mrr.cm/ZPU

1. www.MarketResearchReports.com
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: June 20, 2014
 Number of Pages: 177
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 5,995
Price For Site License: USD 11,990
Price For Global User License: USD 17,985
Delivery Time: Within 24 Hours (During Working Days)

3. www.MarketResearchReports.com
About the Report
Despite its considerable patient population, the acne
market has been overlooked and remained stagnant for
the last decade. There has been a lack of research efforts
due to the perception of a poor return on investment for
topical treatments, the mainstay of acne therapy.
There is an array of treatment options for acne, though
with the exception of isotretinoin, most only provide
symptomatic relief as opposed to a curative or disease-
modifying solution.

4. www.MarketResearchReports.com
Research Findings
The main drivers of growth in the acne market during the 2012-
2018 forecast period include the launch of AndroScience’s ASC-
J9, a therapeutic that is highly anticipated in the previously
stagnant acne market and will make hormonal therapies
available to males with acne, the continued success and uptake
of Galderma’s Epiduo, and the launch of Photocure’s Visonac;
potentially the first photodynamic therapy for use in acne.
The lack of dedicated R&D programs in acne has been
attributed to pharmaceutical companies viewing topicals, the
mainstay of acne therapy, as being inexpensive, with a poor
return on investment. Instead, R&D strategies have centered on
reformulations of existing products and/or fixed-dose
combination therapies, acquisitions of key dermatology products
by Big Pharma, and label expansions into the previously
untapped pediatric market.

5. www.MarketResearchReports.com
Research Findings Continues…
A continued unmet need for acne is the need for new and
innovative products to treat the underlying condition. Ideally,
these products should be molecules that can specifically target
critical pathways in the acne pathophysiology. Given the acne
market’s substantial patient pool (estimated to be 103.9 million
patients in the US and 5EU) and increasing understanding of the
disease’s pathophysiology.
Publisher estimates the 2012 pharmacological therapy sales for
acne to total approximately $2.3 billion across the six major
pharmaceutical markets (6MM) covered within this report: the
US, France, Germany, Italy, Spain, and the UK. The US
contributes 91% of these sales, generating an estimated $2.1
billion in 2012. With $207.0m in sales from the 5EU, Germany
was the largest market with an estimated $54.3m in sales in
2012.

6. www.MarketResearchReports.com
Research Findings Continues…
By the end of the forecast period in 2018, acne sales are
forecast to reach over $2.8 billion, growing at a compound
annual growth rate (CAGR) of 3.9% over the six-year forecast
period. The majority of sales will come from the US, which will
maintain its 2012 lead and command 93% of the market in 2018.
Another corporate trend is the strategic acquisition of key
dermatology products by Big Pharma. A notable event in 2009
involved the acquisition of Stiefel, a leading dermatology
company, by GSK for $3.6 billion.

7. www.MarketResearchReports.com
Scope
Overview of acne, including epidemiology, etiology, pathophysiology,
symptoms, and current treatment options.
Annualized acne prescription therapeutics market revenue, annual cost
of therapy and treatment usage pattern data from 2012 to 2018.
Key topics covered include strategic product assessment, market
characterization, unmet needs, R&D strategies, clinical trial design, and
benchmarking analysis for the acne prescription therapeutics market.
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of late
stage pipeline drugs. Accompanied by an interactive clinical and
commercial benchmarking analysis tool.
Analysis of the current and future market competition in the US and
5EU acne prescription therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.

8. www.MarketResearchReports.com
Report Coverage
1. Table of Contents
2. Introduction
3. Disease Overview
4. Epidemiology
5. Current Treatment Options
6. Unmet Needs Assessment and Opportunity Analysis
7. R&D Strategies
8. Pipeline Assessment
9. Pipeline Valuation Analysis
10.Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

9. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center

10. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/ZPU
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)